GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Shiller PE Ratio

AVANIR Pharmaceuticals (FRA:AV2B) Shiller PE Ratio : (As of May. 17, 2024)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AVANIR Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for AVANIR Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Shiller PE Ratio Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.81 -3.98 - - -

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AVANIR Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Shiller PE Ratio falls into.



AVANIR Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AVANIR Pharmaceuticals's E10 for the quarter that ended in Sep. 2014 is calculated as:

For example, AVANIR Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2014 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2014 (Change)*Current CPI (Sep. 2014)
=-0.064/100.4278*100.4278
=-0.064

Current CPI (Sep. 2014) = 100.4278.

AVANIR Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200412 -0.224 80.290 -0.280
200503 -0.432 81.555 -0.532
200506 -0.255 82.062 -0.312
200509 -0.038 83.876 -0.045
200512 -0.270 83.032 -0.327
200603 -0.366 84.298 -0.436
200606 -0.442 85.606 -0.519
200609 -0.553 85.606 -0.649
200612 -0.295 85.142 -0.348
200703 -0.196 86.640 -0.227
200706 -0.171 87.906 -0.195
200709 0.135 87.964 0.154
200712 -0.089 88.616 -0.101
200803 -0.077 90.090 -0.086
200806 -0.013 92.320 -0.014
200809 -0.047 92.307 -0.051
200812 -0.052 88.697 -0.059
200903 -0.046 89.744 -0.051
200906 -0.043 91.003 -0.047
200909 -0.059 91.120 -0.065
200912 -0.041 91.111 -0.045
201003 -0.059 91.821 -0.065
201006 -0.049 91.962 -0.054
201009 -0.079 92.162 -0.086
201012 -0.083 92.474 -0.090
201103 -0.086 94.283 -0.092
201106 -0.090 95.235 -0.095
201109 -0.105 95.727 -0.110
201112 -0.091 95.213 -0.096
201203 -0.098 96.783 -0.102
201206 -0.088 96.819 -0.091
201209 -0.067 97.633 -0.069
201212 -0.069 96.871 -0.072
201303 -0.093 98.209 -0.095
201306 -0.061 98.518 -0.062
201309 -0.180 98.790 -0.183
201312 -0.051 98.326 -0.052
201403 -0.058 99.695 -0.058
201406 -0.059 100.560 -0.059
201409 -0.064 100.428 -0.064

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AVANIR Pharmaceuticals  (FRA:AV2B) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


AVANIR Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines